Gene-edited hematopoietic stem cells for leukemia and lymphoma treatment: a systematic review of preclinical and translational evidence.

ABSTRACT:

Background

Hematopoietic stem cells (HSCs) are pivotal in regenerating the blood and immune systems and have been widely used in treating hematologic malignancies like leukemia and lymphoma. Advances in gene-editing technologies, such as CRISPR/Cas9 and lentiviral vectors, have enabled the modification of HSCs to enhance their therapeutic potential, offering a continuous source of tumor-targeting immune cells. However, challenges related to long-term engraftment, safety, and delivery mechanisms remain.

Methods

This systematic review, following PRISMA guidelines, evaluated 19 preclinical and translational studies on gene-edited HSCs for leukemia and lymphoma treatment. The review focused on gene-editing methodologies, preclinical outcomes, delivery challenges, and translation

SUBMITTER: Nourmohammadi H 

PROVIDER: S-EPMC12491117 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature